Updated:
Syner-G Pharma Consulting
Syner-G Pharma Consulting was established as a niche consultancy serving pharmaceutical and biotechnology companies requiring deep technical expertise in...
Syner-G Pharma Consulting
Syner-G Pharma Consulting was established as a niche consultancy serving pharmaceutical and biotechnology companies requiring deep technical expertise in drug development. The firm's practice centers on CMC regulatory strategy, formulation development, and manufacturing science — functions that determine whether a therapeutic candidate can be produced reliably and at scale. Rather than competing with generalist life-science consultancies, Syner-G occupies a technical advisory layer that larger contract research organizations and in-house regulatory teams often need to supplement during critical filing periods. The firm advises on the full development lifecycle, from pre-IND strategy through NDA and BLA submission, with particular emphasis on integrating quality-by-design principles into manufacturing processes. Its work spans small-molecule solid-dosage forms, parenteral formulations, and biologic characterization — asset classes that carry distinct supply-chain and stability challenges. Confirmed areas of practice include drug-product formulation development, analytical method validation, and technical writing for Module 3 submissions. The firm guides clients through interactions with the FDA and EMA, structuring responses to agency information requests and preparing teams for pre-approval inspections. Operating from Southborough, Massachusetts, Syner-G serves a client base concentrated in the Northeast biotech corridor, with additional reach into emerging pharmaceutical markets in Europe. The firm's principals draw on decades of large-pharma and contract-manufacturing experience, typically engaging through retainer-based scientific advisory arrangements rather than transaction-dependent fee structures. The practice maintains a deliberately lean staffing model, bringing in former regulatory reviewers and analytical chemists on a project basis to match the specialized requirements of each submission. The structural differentiator is Syner-G's exclusive focus on the CMC discipline — a technical domain where regulatory failure can delay a drug's approval by years. Unlike full-service regulatory consultancies that staff generalists across preclinical, clinical, and post-market functions, Syner-G's entire practice is built around the manufacturing and quality sciences that determine whether a promising molecule becomes a commercial product.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Southborough
Corporate office
Southborough, MA, United States
Sector focus
Frequently asked questions
What specific areas of pharmaceutical development does Syner-G Pharma Consulting advise on?
The firm focuses on chemistry, manufacturing, and controls (CMC) — the discipline that ensures a drug product can be manufactured consistently and meets quality standards. Its work covers formulation development for small molecules and biologics, analytical method validation, stability study design, and technical writing for regulatory submissions. This includes preparing the Module 3 sections of INDs, NDAs, and BLAs for FDA and EMA review.
How does Syner-G differentiate from a full-service regulatory consultancy?
Syner-G restricts its practice entirely to CMC and pharmaceutical development sciences, declining to staff generalist roles in clinical trial design, preclinical toxicology, or commercial strategy. This narrow mandate means the firm deploys specialists — former FDA reviewers, analytical chemists, and formulation scientists — rather than regulatory generalists who cover multiple submission modules. For a sponsor facing a complex manufacturing-related agency hold, that depth is the firm's core proposition.
Does Syner-G Pharma Consulting take equity or royalty positions in client companies?
There is no public record of Syner-G accepting equity, royalties, or success-based fees from client programs. The firm appears to operate on a fee-for-service or retainer model, consistent with the independence requirements that pharmaceutical sponsors expect from a technical advisory practice that interacts directly with regulators.
What geographic markets does Syner-G serve?
The firm is based in Southborough, Massachusetts, positioning it within the dense life-sciences cluster that runs from Cambridge through the Route 128 and I-495 corridors. Its client engagements extend to biotech firms in New Jersey, the Mid-Atlantic, and select European pharmaceutical markets where sponsors require FDA-facing CMC strategy.
What types of dosage forms and modalities does the firm have experience with?
Syner-G's practice covers solid oral dosage forms — tablets and capsules — as well as parenteral formulations including injectables. The firm also addresses biologic characterization, which involves analytical techniques specific to large-molecule therapeutics such as monoclonal antibodies and recombinant proteins. This cross-modality capability is uncommon in smaller CMC consultancies, which typically specialize in either small molecules or biologics but not both.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: